ArticleJournal of inflammation research2026
GSDMD Promotes Epithelial-Mesenchymal Transition and Lymph Node Metastasis in Cervical Cancer in vitro and in vivo.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node metastasis (LNM) is a critical determinant of prognosis in cervical cancer (CC). Tumor-associated macrophages (TAMs) and inflammatory signaling within the tumor microenvironment have been implicated in metastatic progression; however, the molecular mechanisms linking inflammation to lymphatic dissemination remain poorly understood. Methods: We integrated single-cell RNA sequencing (scRNA-seq) of paired primary tumors and metastatic lymph nodes tissues from a single representative patient with clinical histological validation. Functional roles of gasdermin D (GSDMD) were evaluated using in vitro assays, including proliferation, migration, invasion, ELISA, and RNA sequencing, as well as in vivo xenograft and lymph node metastasis models. Results: Single-cell transcriptomic profiling revealed significant activation of pyroptosis-related pathways in metastatic lymph nodes, accompanied by enhanced tumor-stromal interactions. Clinical tissue validation confirmed that GSDMD protein was significantly enriched in metastatic lesions compared to primary tumors. In vitro functional experiments demonstrated that GSDMD promotes epithelial-mesenchymal transition (EMT), enhances migration and invasion, and upregulates VEGFA and VEGFC expression. Mechanistically, GSDMD facilitated the release of pro-inflammatory cytokines such as IL-1β, contributing to a pro-metastatic microenvironment. Notably, GSDMD knockdown suppressed lymph node metastasis in vivo despite promoting primary tumor growth, indicating a context-dependent role in tumor progression. Conclusion: Our findings reveal that GSDMD contributes to the pro-metastatic phenotype of cervical cancer. GSDMD dysregulation correlates with activated EMT and lymphangiogenic signaling, potentially facilitating tumor lymphatic dissemination. This study highlights GSDMD as a promising therapeutic candidate for restraining cervical cancer metastatic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.